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SUPPLEMENTARY NOTES
ABSTRACT
Rationale: Multiple myeloma (MM) is an incurable malignancy derived from antibody secreting B lineage plasma cells. MM is the second most common malignancy in the United States and accounts for 1% of cancer deaths. Despite recent advances, the 5-year survival rate in patients with MM is less than 40% MM responds well to chemotherapy and remissions occur in that majority of MM patients, but all patients eventually relapse and die from progressive disease within 6 years. If the residual post-remission cells of their activation to progressive disease could be disrupted with novel targeted therapies. It would have a significant impact on the care and treatment of MM patients, particularly male veterans who are at 51% increased risk of MM compared to general public. 
a4131 targeted-NPs are cytotoxic for myeloma cell lines
We evaluated the cytotoxicity of the integrin-targeted NPs on myeloma cell lines.
lntegrin avj33 Tg NPs weakly inhibited the growth of KMS-11 and 5TGM1, which was expected as integrin avj33 was not present at significant levels in both the cell lines higher in all the cell lines irrespective of the lntegrin expression levels. Therefore, using
Tg NPs for the delivery of this prodrug showed cytotoxic effects with higher specificity depending on the lntegrin expression of the cell line used.
Key Research Accomplishments:
1. We obtained approval including the locaiiACUC and DoD Office of Research Protection approval.
2.
We performed in vivo efficacy studies of VLA-targeted Sn-2 Myc-inhibitor nanoparticles in mouse models of MM. We have collected blood and tissue for assays to correlate with overall visceral and bone tumor burden and estimate osteoclast and osteoblast activity and tumor burden.
3.
We performed quantitative flow cytometry and histological assessments of bone marrow multiple myeloma tumor cell burden and collateral marrow hematopoietic and stromal populations in response to VLA-targeted Sn-2 Myc-inhibitor nanoparticles.
Conclusion:
We have completed initial testing of VLA-4-targeted, anti-Myc nanoparticles and have found specific and significant effects using myeloma cell lines. We are now proceeding to the characterization of these nanoparticles in pre-clinical mouse models of myeloma that we have "up and running" in the laboratory. We are currently investigating the effects of anti-Myc nanoparticles on tumor cells and normal tissues of mice.
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